A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I studyUrsula Wiedermann, Christoph Zielinski, Rupert Bartsch et al.|Breast Cancer Research and Treatment|2009Cited by 120
Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedulesAngelika Wagner, Ursula Wiedermann, Erika Garner‐Spitzer et al.|Scientific Reports|2018Cited by 113
Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization programLukas Richter, Ursula Wiedermann, Daniela Schmid et al.|PLoS ONE|2019Cited by 45
Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant MontanideJoshua Tobias, Ursula Wiedermann, Christoph Zielinski et al.|BMC Cancer|2017Cited by 44